AQ4N: our lead clinical programme
AQ4N is OncoTherics’ lead clinical-stage asset, with an initial focus on glioblastoma. It is a unidirectional hypoxia-activated prodrug designed to target cancer cells in low-oxygen regions of tumours.
Its development is supported by previous clinical experience and published evidence of activation in human tumour tissue.
OCT1002: the next generation
OCT1002 is our separately patented, second-generation unidirectional hypoxia-activated prodrug in advanced preclinical development.
Its initial focus is prostate cancer, with potential applications in other hypoxic solid tumours. Published preclinical research supports its potential to target treatment-resistant cancer cells.